Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EPS (Basic) (2016 - 2026)

Amphastar Pharmaceuticals has reported EPS (Basic) over the past 13 years, most recently at $0.53 for Q4 2025.

  • For Q4 2025, EPS (Basic) fell 32.91% year-over-year to $0.53; the TTM value through Dec 2025 reached $2.1, down 36.17%, while the annual FY2025 figure was $2.1, 36.17% down from the prior year.
  • EPS (Basic) for Q4 2025 was $0.53 at Amphastar Pharmaceuticals, up from $0.38 in the prior quarter.
  • Over five years, EPS (Basic) peaked at $1.01 in Q3 2023 and troughed at $0.11 in Q1 2021.
  • A 5-year average of $0.57 and a median of $0.54 in 2023 define the central range for EPS (Basic).
  • Biggest five-year swings in EPS (Basic): surged 675.0% in 2021 and later plummeted 54.22% in 2025.
  • Year by year, EPS (Basic) stood at $0.41 in 2021, then soared by 70.73% to $0.7 in 2022, then rose by 7.14% to $0.75 in 2023, then grew by 5.33% to $0.79 in 2024, then tumbled by 32.91% to $0.53 in 2025.
  • Business Quant data shows EPS (Basic) for AMPH at $0.53 in Q4 2025, $0.38 in Q3 2025, and $0.66 in Q2 2025.